China 8 Year Exporter Canagliflozin And Metformin - Daclatasvir Dihydrochloride – CPF manufacturers and suppliers

8 Year Exporter Canagliflozin And Metformin - Daclatasvir Dihydrochloride – CPF

Short Description:

Product Detail

Product Tags

Feedback (2)

With our superb management, potent technical capability and strict quality command procedure, we go on to provide our shoppers with trustworthy high-quality, reasonable costs and outstanding services. We goal at becoming considered one of your most trustworthy partners and earning your pleasure for Ticagrelor Tablet Uses, Pregabalin And Methylcobalamin, Doxycycline Hyclate Uses, Welcome to post your sample and color ring to let us produce according to your specification.Welcome your inquiry! Looking forward to building long-term cooperation with you!

8 Year Exporter Canagliflozin And Metformin - Daclatasvir Dihydrochloride – CPF Detail:

Description

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 µM and 3.27 µM, respectively.

IC₅₀ & Target

EC50: 50 pM (HCV replicon genotype 1a), 9 pM (HCV replicon genotype 1b), 71 pM (HCV replicon genotype 2a), 146 pM (HCV replicon genotype 3a), 12 pM (HCV replicon genotype 4a) and 33 pM (HCV replicon genotype 5a)^[1]
Kd: 8 nM (NS5A33-202) and 210 nM (NS5A26-202)^[2]
IC50: 1.5 µM (OATP1B) and 3.27 µM (OATP1B3)^[3]

In Vitro

Daclatasvir (BMS-790052) demonstrates potent inhibitory activity towards all genotypes tested, with EC₅₀ values ranging from 9 pM to 146 pM. Daclatasvir inhibits HCV replicon genotype 1a, 1b, 2a, 3a, 4a and 5a with EC₅₀ values of 50 pM, 9 pM, 71 pM, 146 pM, 12 pM and 33 pM, respectively. Daclatasvir is a potent inhibitor of the JFH-1 genotype 2a infectious virus that replicates in cell culture (EC₅₀=28 pM)^[1]. Daclatasvir (BMS-790052) binds tightly to NS5A33-202 and NS5A26-202 with K_ds of 8 nM and 210 nM, respectively^[2].

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03369327	Tehran University of Medical Sciences\|RojanPharma Pharmaceutical Company	Hepatitis C Virus Infection, Response to Therapy of\|Human Immunodeficiency Virus	January 1, 2017	Phase 3
NCT03485846	R-Pharm\|Almedis	Chronic Hepatitis C Genotype 1b	November 27, 2017	Phase 2
NCT01016912	Bristol-Myers Squibb	Hepatitis C Infection	December 2009	Phase 2
NCT01629732	Bristol-Myers Squibb	Hepatitis C Virus	March 2013	Phase 2
NCT01497834	Bristol-Myers Squibb	Hepatitis C	January 2012	Phase 3
NCT01973049	Bristol-Myers Squibb	Hepatitis C	December 2013	Phase 3
NCT00663208	Bristol-Myers Squibb	Chronic Hepatitis C	May 2008	Phase 2
NCT02576314	Humanity and Health Research Centre\|Beijing 302 Hospital	Chronic Hepatitis C Infection	May 2015	Phase 3
NCT02756936	Genuine Research Center, Egypt\|Zeta Pharma Pharmaceutical Industries	Healthy	February 2016	Phase 1
NCT02771405	National Hepatology & Tropical Medicine Research Institute\|Cairo University	Hepatitis C, Chronic\|Hepatocellular Carcinoma	March 2016	Phase 3
NCT03706898	Viriom	HIV-1-infection\|Hepatic Impairment	October 1, 2018	Phase 1
NCT02319031	Bristol-Myers Squibb	Hepatitis C	February 2015	Phase 3
NCT02124044	National Institutes of Health Clinical Center (CC)\|National Institute of Allergy and Infectious Diseases (NIAID)\|Bristol-Myers Squibb	HIV-HCV	February 2014	Phase 2
NCT02551861	Bristol-Myers Squibb	Hepatitis C	December 2015	Phase 2
NCT00859053	Bristol-Myers Squibb	Hepatic Insufficiency	March 2009	Phase 1
NCT01257204	Bristol-Myers Squibb	Hepatitis C Virus	December 2010	Phase 2
NCT03063879	Tehran University of Medical Sciences\|Ahvaz Jundishapur University of Medical Sciences\|Shiraz University of Medical Sciences\|Hamadan University of Medical Science	Hepatitis C, Chronic\|Chronic Renal Failure	April 1, 2017	Phase 4
NCT01017575	Bristol-Myers Squibb	Hepatitis C Infection	December 2009	Phase 2
NCT02865369	Sang Gyune Kim\|Seoul National University Boramae Hospital\|Severance Hospital\|Inha University Hospital\|Korea University\|Gachon University Gil Medical Center\|Hanyang University Seoul Hospital\|Ewha Womans University Mokdong Hospital\|Bristol-Myers Squibb\|Soonchunhyang University Hospital	Chronic Hepatitis C	September 2016
NCT04070235	Nanjing Sanhome Pharmaceutical, Co., Ltd.	Hepatitis C, Chronic	March 29, 2019	Phase 2\|Phase 3
NCT03487848	Bristol-Myers Squibb	Hepatitis C\|Chronic Hepatitis	May 18, 2018	Phase 2
NCT00904059	Bristol-Myers Squibb	Hepatitis C	May 2009	Phase 1
NCT02107365	French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)\|Bristol-Myers Squibb	Hepatitis C Virus Genotype 4 Infection	November 2013	Phase 2
NCT02397395	Janssen R&D Ireland	Renal Impairment\|End-stage Renal Disease	May 2015	Phase 2
NCT03169348	Assiut University	Hepatitis C	November 1, 2017	Not Applicable
NCT02323594	Bristol-Myers Squibb	Hepatitis C Infection	December 2014	Phase 1
NCT03537196	French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)	Hepatitis C\|Drug Use\|Viral Hepatitis C	November 13, 2018	Phase 4
NCT02103569	Bristol-Myers Squibb	Hepatitis C	April 2014	Phase 1
NCT02772744	Zagazig University\|Cairo University	Hepatitis C	November 1, 2017
NCT01718158	Bristol-Myers Squibb	Hepatitis C	January 2013	Phase 3
NCT02496078	Bristol-Myers Squibb	Hepatitis C	August 2015	Phase 3
NCT01425970	Bristol-Myers Squibb	Hepatitis C	May 2012	Phase 2
NCT01471574	Bristol-Myers Squibb	Hepatitis C, Genotype 1	December 2011	Phase 3
NCT01573351	Bristol-Myers Squibb	Hepatitis C Virus	May 2012	Phase 3
NCT01938625	Janssen R&D Ireland	Hepatitis C, Chronic	December 12, 2013	Phase 2
NCT01492426	Bristol-Myers Squibb	Hepatitis C	January 2012	Phase 3
NCT03480932	Johns Hopkins Bloomberg School of Public Health\|National Institute on Drug Abuse (NIDA)\|YR Gaitonde Centre for AIDS Research and Education	Hepatitis C, Chronic	February 2, 2018	Phase 2\|Phase 3
NCT03163849	Assiut University	Chronic Hepatitis c	September 1, 2019	Phase 3
NCT01581203	Bristol-Myers Squibb	Hepatitis C Virus	May 2012	Phase 3
NCT01492504	Bristol-Myers Squibb	Hepatitis C	February 7, 2012
NCT03686722	Mohamed Raslan\|Ain Shams University\|Drug Research Centre, Cairo, Egypt	Diabetes Mellitus, Type 2\|Hepatitis C\|Drug Interactions	September 9, 2017	Phase 1
NCT02262728	Janssen Research & Development, LLC	Hepatitis C, Chronic	September 30, 2014	Phase 2
NCT02349048	Janssen Research & Development, LLC	Hepatitis C Virus	January 2015	Phase 2
NCT03882307	Assiut University	Hepatitis C, Chronic	May 2020	Early Phase 1
NCT02758509	Parc de Salut Mar	Chronic Hepatitis C\|Cirrhosis	January 1, 2010
NCT01795911	Bristol-Myers Squibb	Hepatitis C	March 2013	Phase 2
NCT03549832	Assiut University\|Sohag University\|South Valley University	HCV Coinfection	January 1, 2018	Not Applicable
NCT02161939	Bristol-Myers Squibb	Chronic Hepatitis C
NCT01309932	Bristol-Myers Squibb	Hepatitis C	March 2011	Phase 2
NCT01995266	Bristol-Myers Squibb	Hepatitis C	February 28, 2014	Phase 3
NCT02640157	AbbVie	Chronic Hepatitis C\|Hepatitis C Virus\|Genotype 3 Hepatitis C Virus	December 2015	Phase 3
NCT02032875	Bristol-Myers Squibb	Hepatitis C	March 2014	Phase 3
NCT02624063	Federal University of São Paulo	Hepatitis C, Chronic	December 2015	Phase 4
NCT00546715	Bristol-Myers Squibb	Chronic Hepatitis C	November 2007	Phase 1\|Phase 2
NCT01718145	Bristol-Myers Squibb	Hepatitis C Virus Infection	November 2012	Phase 3
NCT01616524	Bristol-Myers Squibb	Hepatitis C Virus (HCV)	July 2012	Phase 3
NCT02032901	Bristol-Myers Squibb	Hepatitis C	January 2014	Phase 3
NCT03540212	Ain Shams University	Chronic HCV Infection	December 10, 2017	Phase 2\|Phase 3
NCT02097966	Bristol-Myers Squibb	Chronic Hepatitis C
NCT02596880	Tehran University of Medical Sciences	Hepatitis C\|Cirrhosis	September 2015	Phase 3
NCT04019717	Atea Pharmaceuticals, Inc.	Hepatitis C\|Hepatitis C, Chronic\|Chronic Hepatitis C\|Hepatitis C Virus Infection\|HCV Infection	June 20, 2019	Phase 2
NCT02992457	Tanta University	Hepatitis C	January 2015	Phase 4
NCT03547895	Zagazig University	Decompensated Cirrhosis	June 1, 2015	Not Applicable
NCT03004625	Kaohsiung Medical University Chung-Ho Memorial Hospital\|Chang Gung Memorial Hospital\|National Taiwan University Hospital\|Taipei Veterans General Hospital, Taiwan\|China Medical University Hospital\|National Cheng-Kung University Hospital	Hepatitis C	November 2016	Phase 3
NCT01051414	Bristol-Myers Squibb	Hepatitis C Infection	April 2010	Phase 2
NCT02309450	French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)\|Bristol-Myers Squibb	Hepatitis C Virus Genotype 4 Infection	December 2014	Phase 2
NCT01628692	Bristol-Myers Squibb\|Janssen Research & Development, LLC	Hepatitis C Virus	July 2012	Phase 2
NCT03186313	Egyptian Liver Hospital\|Wadi El Nil Hospital	Hepatitis C	September 2016	Phase 3
NCT03063723	Third Affiliated Hospital, Sun Yat-Sen University	Chronic Hepatitis C (Disorder)	January 1, 2016
NCT00983957	Bristol-Myers Squibb	Chronic Hepatitis C	October 2009	Phase 1
NCT01725542	French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)\|Bristol-Myers Squibb	HCV-HIV Co-Infection	December 2012	Phase 2
NCT02282709	Foundation for Liver Research	Chronic Hepatitis C	February 2014	Phase 3
NCT02032888	Bristol-Myers Squibb	Hepatitis C	February 2014	Phase 3
NCT03247296	MTI University	Hepatitis C	February 28, 2017
NCT01389323	Bristol-Myers Squibb	Hepatitis C	September 2011	Phase 3
NCT02556086	Bristol-Myers Squibb	Hepatitis C	December 2015	Phase 2
NCT01741545	Bristol-Myers Squibb	Hepatitis C Virus	March 31, 2013	Phase 3
NCT01866930	Bristol-Myers Squibb	Chronic Hepatitis C Infection	July 11, 2013	Phase 3
NCT02268864	Janssen-Cilag International NV	Hepatitis C, Chronic	January 2015	Phase 2
NCT01797848	Bristol-Myers Squibb	Hepatitis C	June 2014	Phase 3
NCT03166280	Eman Sayed Hassan Abd Allah\|Assiut University	Hepatitis C	June 2017
NCT02159352	Bristol-Myers Squibb	Hepatitis C	June 2014	Phase 1
NCT01125189	Bristol-Myers Squibb	Hepatitis C Virus	July 2010	Phase 2
NCT03748745	Nanjing Sanhome Pharmaceutical, Co., Ltd.	Drug Interactions	November 19, 2018	Phase 1
NCT01012895	Bristol-Myers Squibb	Chronic Hepatitis C	December 2009	Phase 2
NCT02565888	Radboud University	Hepatitis C\|HIV	November 2015	Phase 1
NCT02555943	Humanity and Health Research Centre\|Beijing 302 Hospital\|Nanfang Hospital of Southern Medical University	Chronic Hepatitis C Infection\|HBV Coinfection\|Hepatitis B Reactivation	February 2015	Phase 2\|Phase 3
NCT02304159	Tarek I. Hassanein, M.D., FACP, FAG, AGAF\|Southern California Research Center	Hepatitis C\|Cirrhosis	January 2015	Phase 4
NCT02580474	Myeong Jun Song\|Bristol-Myers Squibb\|Soonchunhyang University Hospital\|Dankook University\|Chungnam National University Hospital\|Konyang University Hospital\|Eulji University Hospital\|Saint Vincent´s Hospital, Korea\|Konkuk University Hospital\|Cheongju St. Mary´s Hospital, Cheongju, Korea\|Severance Hospital\|Korea University Guro Hospital\|Eulji General Hospital\|The Catholic University of Korea	Hepatitis C	February 2016	Phase 4
NCT02104843	Bristol-Myers Squibb	Hepatitis C	April 2014	Phase 1
NCT01428063	Bristol-Myers Squibb	Hepatitis C Virus Infection	September 2011	Phase 2
NCT02123654	Bristol-Myers Squibb	Hepatitis C Virus Infection	April 2014	Phase 3
NCT02565862	Radboud University	Hepatitis C\|Diabetes Mellitus\|Insulin Resistance	January 2016	Phase 1
NCT04211844	Ain Shams University	Chronic Hepatitis C	October 1, 2019
NCT00874770	Bristol-Myers Squibb	Hepatitis C Infection	June 2009	Phase 2
NCT03883698	Sanjay Gandhi Postgraduate Institute of Medical Sciences	Kidney Failure, Chronic\|Hepatitis C	March 15, 2019	Phase 3
NCT01448044	Bristol-Myers Squibb	Hepatitis C	December 2011	Phase 3
NCT01359644	Bristol-Myers Squibb\|Pharmasset	Chronic Hepatitis C	June 2011	Phase 2
NCT01842451	Vertex Pharmaceuticals Incorporated	Chronic Hepatitis C\|CHC\|HCV\|Hepatitis C	June 2013	Phase 2
NCT02762448	Tainan Municipal Hospital	Hepatitis c	July 2016
NCT02473211	Humanity and Health Research Centre\|Beijing 302 Hospital	Chronic Hepatitis C Infection	January 2015	Phase 2\|Phase 3
NCT01455090	Bristol-Myers Squibb	Chronic Hepatitis C	November 30, 2011	Phase 2
NCT03490097	Ain Shams University	Chronic Hepatitis c\|Metabolic Syndrome	December 1, 2017	Phase 2\|Phase 3
NCT01170962	Bristol-Myers Squibb	Hepatitis C Virus	August 2010	Phase 2
NCT02333292	Valme University Hospital\|Hospital del SAS de Jerez\|Hospital General Universitario Elche\|Hospital La Línea de la Concepción\|Complexo Hospitalario Universitario de A Coruña\|Hospital de Figueres\|Hospital Universitario Puerto Real\|Hospital Universitario Virgen de la Victoria\|Hospital Universitario de Canarias\|Hospital General Universitario de Alicante\|Hospital Universitario Araba\|Hospital Royo Vilanova\|Hospital Universitario de Burgos\|Complejo Hospitalario Universitario de Huelva\|Hospital Universitario Reina Sofia de Cordoba\|Hospital Universitario Virgen Macarena\|Complexo Hospitalario Universitario de Vigo\|Clinica Universidad de Navarra, Universidad de Navarra\|Hospital Clinico Universitario San Cecilio\|Hospital Universitario La Fe\|Hospital General Universitario de Valencia\|Hospital Universitario Infanta Leonor\|Hospital Universitario de Gran Canaria\|Hospital General Universitario Santa Lucía\|Centro Penitenciario Alicante 1\|Hospital Regional Universitario Carlos Haya\|Hospital Virgen de la Luz\|Hospital General Universitario de Castellón\|Hospital Parc Taulí, Sabadell	Chronic Hepatitis C Infection	December 2014
NCT03200184	Tehran University of Medical Sciences	Hepatitis C	September 1, 2016	Phase 4
NCT03188276	Third Affiliated Hospital, Sun Yat-Sen University	Chronic Hepatitis C	February 1, 2016	Early Phase 1
NCT01830205	Bristol-Myers Squibb	Hepatitis C	September 2012	Phase 1